Investigators: J. Andrew MacKay, Ph.D. Peter Conti, M.D., Ph.D., Alan Epstein, M.D., Ph.D. Zibo Li, Ph.D.
Innovation: Nanoworm-delivered therapeutics that can bind to more than one target
Clinical significance: New immunotherapies tailored to non-Hodgkin’s lymphoma patients

Investigators:Min Yu, M.D., Ph.D. Pin Wang, Ph.D., Julie Lang, M.D.
Innovation: delivering a novel nanoparticle/TAK1 inhibitor to halt metastasis
Clinical significance: a new treatment for metastatic breast cancer

Investigators: Jennica Zaro, Ph.D. Peter Conti, M.D., Ph.D.
Innovation: a method to recognize the minute differences in pH levels near tumor cells
Clinical significance: enabling more powerful cancer-killing drugs to be used without side effects

Investigators: Andrea Armani, Ph.D.; Charles Gomer, Ph.D.; David Agus, M.D.; Qifa Zhou, Ph.D.
Innovation: combining nanotechnology with ultrasound waves
Clinical significance: increasing the penetration depth of nanoparticle- enhanced therapy to reach previously inaccessible tumors

Investigators: Wei Wu, Ph.D.; Mahta Moghaddam, Ph.D.; John Stang, Ph.D.; Eugene Chung, M.D., Ph.D., J.D.
Innovation: a new class of custom-engineered nanoparticles that enhance absorption at microwave frequencies
Clinical significance: noninvasive, less painful therapy, especially beneficial for patients unable to undergo surgery